Gayatri Iyer | Pharmacogenomics | Best Researcher Award

Dr. Gayatri Iyer | Pharmacogenomics | Best Researcher Award

Scientist III at Tata Institute for Genetics and Society, India

Dr. Gayatri R. Iyer is a leading clinical geneticist and molecular biologist specializing in genetic counseling and rare disease diagnostics. With over a decade of hands-on experience in both research and clinical genetics, she bridges molecular science with patient-centric healthcare. She currently serves as Scientist Grade II at the Tata Institute for Genetics and Society, where she develops cost-effective diagnostic solutions for complex genetic disorders. Certified at Level II by the Board of Genetic Counseling, India, and holding an INSPIRE fellowship from the Department of Science and Technology, her professional journey reflects excellence in research, diagnostics, and community outreach. Her multidisciplinary expertise and contributions make her a standout nominee in the field of translational genetics.

profile

google scholar

Education

Dr. Iyer’s academic foundation is built on a rigorous and multidisciplinary path. She earned her Ph.D. in Human Genetics from Kamineni Hospitals, affiliated with Osmania University, where she was a DST-INSPIRE Fellow (2016–2021). Her doctoral research focused on developing methylation-specific PCR assays for imprinting disorders, reflecting her dedication to translating molecular diagnostics into clinical practice. She completed her M.Sc. in Applied Genetics from The Oxford College of Science, Bangalore, with a gold medal for academic excellence (2012–2014), and secured second rank in her B.Sc. in Biotechnology from Birla College, Mumbai (2012). She has supplemented her academic training with a PG Certificate in Medical & Genetic Counseling and a diploma in Bioinformatics.

Experience

With progressive experience in clinical genetics, Dr. Iyer has held diverse roles across premier institutions. At the Tata Institute for Genetics and Society (2023–present), she focuses on developing diagnostic platforms for rare disorders such as imprinting syndromes and neuromuscular conditions. During her postdoctoral fellowship at IIT Bombay (2022–2023), she worked on subcellular proteomics and gut microbiome sequencing. At Kamineni Hospitals, Hyderabad (2015–2021), she evolved from a Junior to Senior Research Fellow and served as a senior genetic counselor, managing over 2,000 cases across specialties including pediatrics, oncology, and reproductive medicine. Her work at LifeCell International and Datar Genetics further solidified her position as an expert counselor and educator.

Research Interest

Dr. Iyer’s research is centered on rare genetic diseases, molecular diagnostics, pharmacogenomics, and genetic counseling. She is especially focused on developing accessible and cost-effective diagnostic tools for Indian and resource-limited populations. Her doctoral work on imprinting disorders was groundbreaking, contributing novel diagnostic pathways for syndromes like Prader-Willi and Angelman. She is equally invested in epigenetics, next-generation sequencing, and microarray-based diagnostics. Her translational approach ensures that molecular insights are effectively integrated into patient care, family screening, and policy development. She continues to bridge the gap between lab-based discoveries and real-world clinical applications through genetic counseling and education.

Awards

Dr. Iyer’s contributions have been consistently recognized at national and international levels. She is the recipient of the DST Faculty Research Grant (2024–2029) and co-investigator on an ICMR CAR grant. Her global reputation was affirmed by receiving a $3,500 workshop grant and a travel grant from the International Prader-Willi Syndrome Organization. She was awarded the prestigious DST-INSPIRE Fellowship (2016–2021) and secured a travel grant to present her research at the Asia Pacific Prader-Willi Conference in Brisbane (2018). Her academic accolades include the Gold Medal in M.Sc. Applied Genetics and first rank in her Bioinformatics diploma. She also serves as Joint Secretary of the Executive Committee, Board of Genetic Counseling, India.

Publications

Dr. Iyer has contributed to over 15 peer-reviewed journal articles and book chapters. Selected impactful publications include:

Halder A, Iyer G, et al. (2023). Targeted proteomics distinguishes high and low grade meningioma tumors. Clin Proteomics, 20(1):41. [Cited by: 5]

Bajaj S, Iyer G, et al. (2022). Telegenetics diagnosis of Hunter syndrome during COVID-19. Int J Contemp Pediatr, 9:851–4. [Cited by: 2]

Iyer GR, et al. (2022). NGS in musculoskeletal disorders. J Orthop Surg Res, 17(1):76. [Cited by: 3]

Iyer GR, et al. (2021). Angelman syndrome phenotype with GABRG3. Ann Hum Genet, doi:10.1111/ahg.12449. [Cited by: 4]

Abbas NZ, Iyer GR, et al. (2020). Genotype-Phenotype correlation in pediatric neurology. Int J Health Clin Res, 3(5):67–73. [Cited by: 2]

Iyer G, et al. (2020). COVID-19 therapy driven by pharmacogenomics. AIJR Preprints. [Cited by: 7]

Iyer GR, et al. (2020). Host gene variants and COVID-19 progression. Front Genet, 11:861. [Cited by: 10]

Conclusion

Dr. Gayatri R. Iyer exemplifies the ethos of a best researcher through her unwavering commitment to bridging science and clinical application. Her pioneering work in low-cost diagnostic development for rare disorders, hands-on clinical counseling experience, interdisciplinary teaching, and highly cited publications affirm her exceptional contribution to medical genetics and public health. Her nomination for the Best Researcher Award is a recognition of her dedication, innovation, and leadership in translating genetic research into impactful health solutions.

Shuying FENG | Functional Genomics | Best Researcher Award

Prof. Shuying FENG | Functional Genomics | Best Researcher Award

Director at Henan University of Chinese Medicine, China.

Dr. Shuying Feng is a Professor, PhD, and Postdoctoral Supervisor at Henan University of Chinese Medicine, where he leads several key research centers focused on functional and special medical foods. A nationally recognized expert in traditional Chinese medicine, his work integrates nanotechnology, probiotic fermentation, gene editing, and the medical application of natural products. Dr. Shuying Feng has published over 100 papers (90+ SCI-indexed), holds 21 national invention patents, and has directed numerous national and provincial projects. He is also a distinguished academic leader, mentor, and recipient of multiple scientific and technological awards.

🎓 Academic Background :

Dr. Shuying Feng is a highly accomplished Professor and Doctoral/Postdoctoral Supervisor at Henan University of Chinese Medicine. Holding a PhD and serving as a leading scholar in his field, Dr. Shuying Feng is also a member of the Communist Party of China. He currently leads several prominent research institutions, including the Henan Engineering Research Center for Special Medical Foods of Traditional Chinese Medicine, and serves as Executive Director of the Institute of Functional Foods and Medicine-Food Homologous Research. His academic leadership has significantly influenced the advancement of traditional Chinese medicine and functional food research across Henan Province and beyond.

Profile:

Professional Experience:

Dr. Shuying Feng has extensive professional experience as a professor, researcher, and academic leader in the field of traditional Chinese medicine and functional foods. He currently serves as Director of multiple research centers, including the Henan Engineering Research Center for Special Medical Foods, and holds executive roles at key provincial and municipal laboratories. Over his career, he has led more than 30 national, provincial, and industry-funded research projects, secured significant research funding, and guided numerous graduate and postdoctoral researchers. His work has resulted in over 100 publications, 21 national patents, and wide-ranging contributions to both academic and industrial advancements in medical food innovation.

🔬 Research Interests:

Dr. Shuying Feng’s research spans several pioneering fields within biomedical science and traditional medicine. His primary areas of interest include the development of functional and special medical foods, the nanoization and probiotic fermentation enhancement of traditional Chinese medicine, gene editing and its applications in microalgae, and the medical applications of bee products. His multidisciplinary approach bridges ancient medicinal wisdom with cutting-edge biotechnology, driving innovation in both health and food sciences.

🏅 Honors & Recognition:

Dr. Shuying Feng has been recognized with numerous accolades, including the title of Distinguished Professor of Henan Province, High-Level Talent (Category C), Academic and Technical Leader by the Henan Department of Education, and Outstanding Young Backbone Teacher in Higher Education. At the city level, he has been named an Excellent Scientific and Technological Talent. These honors underscore his contributions to both academic excellence and public service in the field of medical science.

🏛️ Leadership & Roles:

Beyond his research and teaching, Dr. Feng holds influential roles in academic societies. He is Vice Chairman of the Tumor Cell Professional Committee of the Henan Cell Biology Society and a council member of both the Fermentation Research Committee under the World Federation of Chinese Medicine Societies and the Henan Biochemistry and Molecular Biology Society. These leadership positions highlight his commitment to collaborative scientific advancement and community engagement.

Publications:

  • Meng, Y., Si, Y., Guo, T., Sun, K., & Feng, S. (2025). Ethoxychelerythrine as a potential therapeutic strategy targets PI3K/AKT/mTOR induced mitochondrial apoptosis in the treatment of colorectal cancer. Scientific Reports.
    🔹 Citations: 1

  • Ji, C., Li, S., Hu, C., Yin, S., & Feng, S. (2024). Traditional Chinese medicine as a promising choice for future control of PEDV. (Journal name not specified).
    🔹 Citations: 0

  • Zhang, B., Wang, Q., Zhang, Y., Wang, B., & Feng, S. (2024). Treatment of insomnia with traditional Chinese medicine presents a promising prospect. (Journal name not specified).
    🔹 Citations: 0

  • Yang, Y., Li, S., Shi, W., Lu, B., & Feng, S. (2024). Pterostilbene suppresses the growth of esophageal squamous cell carcinoma by inhibiting glycolysis and PKM2/STAT3/c-MYC signaling pathway. International Immunopharmacology.
    🔹 Citations: 1

  • Wei, W., Guo, T., Fan, W., Ma, W., & Feng, S. (2024). Integrative analysis of metabolome and transcriptome provides new insights into functional components of Lilii Bulbus. Chinese Herbal Medicines.
    🔹 Citations: 5